Bausch + Lomb says FDA supportive in principle of initial study design for oral dry AMD drug BL1243, expects 2027 start

Bausch + Lomb says the FDA is supportive in principle of the initial study design for its oral dry age-related macular degeneration drug BL1243, and expects the study to start in 2027.

Detected & updated continuously · Source: Nebula